Callan Family Office LLC Increases Stock Holdings in Sanofi $SNY

Callan Family Office LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 228.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 235,522 shares of the company’s stock after buying an additional 163,920 shares during the quarter. Callan Family Office LLC’s holdings in Sanofi were worth $11,378,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of SNY. Ameritas Advisory Services LLC purchased a new position in shares of Sanofi in the second quarter valued at approximately $28,000. Accent Capital Management LLC purchased a new position in Sanofi in the first quarter worth approximately $29,000. Eastern Bank raised its holdings in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Sanofi during the first quarter worth approximately $33,000. Finally, Golden State Wealth Management LLC raised its holdings in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after purchasing an additional 545 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SNY. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Stock Up 0.0%

SNY opened at $48.82 on Friday. The firm has a 50 day moving average price of $48.25 and a 200 day moving average price of $49.87. The company has a market cap of $119.88 billion, a PE ratio of 11.74, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm’s revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.73 EPS. Sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.